Red cell volume measurement: using technetium as a replacement for chromium

Letters to the Editor

Nuclear Medicine Communications 2020, 41:1106–1108

Juliette Dinet⁎, David Tonnelet⁎, Joseph Le Cloirec⁎, Stéphanie Becker⁎⁎ and Pierre Bohn⁎⁎,⁎Département de Medecine Nucléaire, Centre Henri Becquerel and ⁵QuantIF-LITIS EA4108, IRIIB, Université de Rouen, Rouen, France

Correspondence to Pierre Bohn, PhD, PharmD, Centre Henri Becquerel, Rouen, France
Tel: +33 2 32 08 29 23; e-mail: pierre.bohn@chb.unicancer.fr

Received 29 May 2020 Accepted 27 June 2020

We read with a great interest the technical note written by Ainslie-McLaren et al. [1] about the red cell volume measurement using indium as a replacement to chromium. We encountered the same issue regarding the GE Healthcare facility’s closure which manufactured ⁵¹Cr-EDTA and ⁵¹CrO₄Na. Like the authors, we had to replace the ⁵¹Cr-EDTA with ⁹⁹ᵐTc-DTPA for the glomerular filtration rate studies. However, unlike the authors, we did not use ¹¹¹In for the labelling of undamaged red blood cells to assess the red cell volume in patients. We labelled erythrocytes with ⁹⁹ᵐTc following the recommendations of the EANM [2]. The authors argue that the ⁹⁹ᵐTc-erythrocytes label is less stable over time than ¹¹¹In label and prevents its use in patients with splenomegaly due to the ¹-h injection delay. Indeed, their study shows that ¹¹¹In-tropolonate has the least elution (<2%) from erythrocytes after a 1-h delay when replacing chromium by technetium and using a stannous pyrophosphate. They found 8% after 1 hour of incubation at 37°C. Previously to this work, Schmidt et al. [7] showed the absence of significant technetium elution from erythrocyte during the first hour when using a stannous pyrophosphate.

But, when stannous weak chelators are used like pyrophosphate (PYP Technescan); it is observed that the stannous pyrophosphate can cross over the erythrocytes’ membrane easily and cause more avid binding on the haemoglobin’s globin chain. The work of Holt et al. [8] showed that the ‘In vitro labelling gives by far the highest labelling efficiency and, over time, the most stable labelling. Measurement of erythrocyte volume by in vitro labelled RBCs with ⁹⁹ᵐTc gives values similar to labelling with the gold standard ⁵¹Cr [2].

Moreover, the short half-life of ⁹⁹ᵐTc makes it possible to ensure counting on the whole blood sampling. We then wait for a radioactive decay (about 3 days) to count ¹²⁵I. No additional procedure is needed in the counting window.

To conclude, until proven otherwise, we will continue to label red blood cells by ⁹⁹ᵐTc as a replacement for ⁵¹Cr [9]. We think this method is simple and robust. This does not detract from the quality of the work on ¹¹¹In erythrocyte labelling with tropolone.

Acknowledgements
Conflicts of interest
There are no conflicts of interest.

References
1 Ainslie-McLaren G, Fee A, McKinstray J, Lee AB, Bolster AA. Red cell volume measurement - using indium as a replacement for chromium. Nucl Med Commun 2020; 41:589–596.
2 Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging 2008; 35:851–885.
3 Morrissey GJ, Gravelle D, Dietz G, Driedger AA, King M, Craddock TD. In vivo red red blood cell compatibility testing using indium-113m tropolone labelled red blood cells. J Nucl Med 1988; 29:684–686.
4 Radia R, Peters AM, Deemnamode M, Fitzpatrick ML, Lewis SM. Measurement of red cell volume and splenic red cell pool using 113m indium. Br J Haematol 1981; 49:587–591.
Bronchopulmonary MDR protein expression may protect against COVID-19 infection

A. Michael Peters and H.K. Mohan
Department of Nuclear Medicine, King’s College Hospital, London and Sri Shankara Cancer Hospital and Research Institute, Bangalore, India

Correspondence to A. Michael Peters, MD, Department of Nuclear Medicine, King’s College Hospital, Denmark Hill, Brixton, London SE5 9RS, UK
Tel: +44 203 299 3440; e-mail: Adrien.peters@nhs.net

Received 18 June 2020 Accepted 14 August 2020

Whether or not otherwise healthy cigarette smokers are less likely to become infected with coronavirus disease (COVID-19) is controversial. The findings in several studies that have reported a lowered prevalence of smoking in hospitalised patients compared with the general population [1–4] have been criticised on the grounds that hospitalised patients tend to be older and that older patients tend not to smoke. However, at least one study controlled for age and gender [4]. That smokers, once hospitalised, have a poorer outcome than nonsmokers [5] is not surprising, but what is not clear is the proportion of smokers in subjects undergoing ‘test and trace’ who test positive for COVID-19 but who are not necessarily symptomatic. In a recent scientific brief, the WHO reported that no such studies have yet been undertaken [5]. However, from the perspective of protection from infection in the first place, these subjects, rather than smoking patients hospitalised and with poor outcomes, form the most important group.

We speculate that otherwise healthy smokers may be protected from COVID-19 infection as the result of upregulation of bronchopulmonary expression of ABC cassette transporter (multi-drug resistance) proteins. These membrane-linked proteins, the best known of which is P-glycoprotein (P-gp), have been likened to rotating doors that inhibit the entrance of or extrude a wide range of foreign substances from cells. In general, they furnish parts of the body that interface with the outside world, such as bronchopulmonary, gastrointestinal and renal tubular epithelia, and bile canaliculi, ‘pumping’ towards the exterior. They are also present in blood–brain barrier, protecting the brain.

In previous work using dynamic gamma camera scintigraphy, we measured the disappearance rate from the lungs of Tc-99m-labelled methoxyisobutylisonitrile (MIBI), administered as an inhaled radioaerosol. This compound, widely used in nuclear medicine, especially for myocardial perfusion imaging, is an multi-drug resistance (MDR) substrate. Interestingly, healthy cigarette smokers showed a striking reduction in clearance rate compared with nonsmokers, the opposite to the clearance rates of Tc-99m-diethylenetriaminepentaacetic acid. Cigarette smoke is full of xenobiotics, raising the strong possibility that bronchopulmonary MDR proteins are upregulated by cigarette smoke and suggesting that the rate of clearance of the tracer across the pulmonary blood–gas barrier could be a quantitative marker of bronchopulmonary MDR protein expression [6], especially P-gp. We subsequently showed, however, that the Tc-99m-MIBI clearance rate strongly correlated with the pulmonary immunohistological expression of MRP1, rather than P-gp, and that expression was increased in smokers [7].

The question, therefore, arises as to whether such upregulation could hinder the cellular entry of viruses. It has been shown that P-gp in T-lymphocytes is capable of extruding hydrophobic peptides essential for the fusion of HIV-1 [8]. Other than HIV-1, however, it is difficult to find publications in the literature relating MDR to the infectivity of viruses.

If the above speculation turns out to be correct, then the administration of ingredients of cigarette smoke, such as nicotine which has been suggested as the mediator of protection in smokers [1], are likely to be ineffective in showing protection if administered via routes other than inhalation. Starting to smoke would potentially be harmful as substrates are initially MDR blockers, with upregulation following later.

Caveats to the above speculation are that in nonsmokers, we found first, no difference in clearance rate between men and women, and second, a trend for clearance to be delayed, rather than accelerated, in older subjects [9]. However, as implied in the WHO scientific brief alluded to above, the known poorer clinical outcome in the elderly and in males is a separate statistic from infection rate itself.

Acknowledgements

Conflicts of interest

There are no conflicts of interest.